A Study to Evaluate ALN-AGT01 in Patients With Hypertension
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03934307 |
Recruitment Status :
Completed
First Posted : May 1, 2019
Last Update Posted : January 17, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension | Drug: ALN-AGT01 Drug: ALN-AGT01-Matching Placebo Drug: Irbesartan Drug: Irbesartan-Matching Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 124 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Dose and Active Comparator-Controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-AGT01 in Patients With Hypertension |
Actual Study Start Date : | May 1, 2019 |
Actual Primary Completion Date : | April 20, 2022 |
Actual Study Completion Date : | January 4, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Part A: SAD: ALN-AGT01
Participants will be administered a single dose of ALN-AGT01.
|
Drug: ALN-AGT01
ALN-AGT01 will be administered by subcutaneous (SC) injection.
Other Name: Zilebesiran |
Placebo Comparator: Part A: SAD: ALN-AGT01-Matching Placebo
Participants will be administered a single dose of ALN-AGT01-matching placebo.
|
Drug: ALN-AGT01-Matching Placebo
Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC. |
Experimental: Part B: SD: ALN-AGT01
Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
|
Drug: ALN-AGT01
ALN-AGT01 will be administered by subcutaneous (SC) injection.
Other Name: Zilebesiran |
Placebo Comparator: Part B: SD: ALN-AGT01-Matching Placebo
Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
|
Drug: ALN-AGT01-Matching Placebo
Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC. |
Experimental: Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo
Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
|
Drug: ALN-AGT01
ALN-AGT01 will be administered by subcutaneous (SC) injection.
Other Name: Zilebesiran Drug: Irbesartan-Matching Placebo Irbesartan-matching placebo will be administered orally. |
Active Comparator: Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan
Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
|
Drug: ALN-AGT01-Matching Placebo
Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC. Drug: Irbesartan Irbesartan will be administered orally. |
Experimental: Part E: Open Label: ALN-AGT01 + Irbesartan
Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.
|
Drug: ALN-AGT01
ALN-AGT01 will be administered by subcutaneous (SC) injection.
Other Name: Zilebesiran Drug: Irbesartan Irbesartan will be administered orally. |
- Number of Participants with Adverse Events (AEs) [ Time Frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months ]
- Change from Baseline in Blood Angiotensinogen (AGT) Level [ Time Frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months ]
- Maximum Observed Plasma Concentration (Cmax) of ALN-AGT01 and of Potential Metabolites [ Time Frame: Parts A, B and E: Up to Day 15; Part D: Up to Day 99 ]
- Area Under the Concentration-time Curve (AUC) of ALN-AGT01 and of Potential Metabolites [ Time Frame: Parts A, B and E: Up to Day 15; Part D: Up to Day 99 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Has mild to moderate hypertension with mean sitting systolic blood pressure (SBP) of >130 and ≤165 mmHg without hypertensive medication for Parts A, B and D, and >135 and ≤165 mmHg without hypertensive medication for Part E
- Parts A and B: Has body mass index (BMI) ≥18 and ≤35 kg/m^2; Part D: Has BMI >35 and ≤50 kg/m^2; Part E: Has BMI ≥18 kg/m^2 and ≤50 kg/m^2
- Has a normal 12-lead electrocardiogram (ECG)
- Is a nonsmoker
Exclusion Criteria:
- Has secondary hypertension
- Has orthostatic hypotension
- Has estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m^2
- Recently received an investigational agent
- Has diabetes mellitus
- Has history of any cardiovascular event
- Has history of intolerance to SC injection(s)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03934307
United Kingdom | |
Clinical Trial Site | |
Edinburgh, United Kingdom | |
Clinical Trial Site | |
London, United Kingdom | |
Clinical Trial Site | |
Manchester, United Kingdom |
Study Director: | Medical Director | Alnylam Pharmaceuticals |
Responsible Party: | Alnylam Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT03934307 |
Other Study ID Numbers: |
ALN-AGT01-001 2019-000129-39 ( EudraCT Number ) |
First Posted: | May 1, 2019 Key Record Dates |
Last Update Posted: | January 17, 2023 |
Last Verified: | January 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hypertension Vascular Diseases Cardiovascular Diseases Irbesartan |
Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |